TRIAL DETAIL

LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-Cell Lymphoma

Drug:
Trial Name:
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-Cell Lymphoma
NCT#:
Conditions:
Tumors, Cutaneous T-Cell Lymphoma
Status:
Completed
Phase:
1
Start Date 11/01/2006
Age of Trial (yrs) 19
Treatment Phase:
Gleevec-resistant
Drug Category:
HDAC inhibitor
Strategy:
Block KIT Unblock cell death genes
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
CLBH589B1101
Sponsor:
Novartis
Patient Contact:
Novartis
Contact email:
Contact Phone:
81-3-3797-8748
Randomized:
IV or Oral:
Oral
Trial Notes:
Unspecified Site in Tokyo, Japan

Please refer to this study by ClinicalTrials.gov identifier NCT00412997

Novartis +81-3-3797-8748

Trial Links

Trial Results

Drug Information
Inhibitors of Deacetylases Suppress Oncogenic KIT Signaling, Acetylate HSP90, and Induce Apoptosis in Gastrointestinal Stromal Tumors
 
Novartis pipeline
 
LBH589, a novel histone deacetylase inhibitor (HDACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Changes in skin gene expression profiles related to clinical response following therapy
 
In the Pipeline: Panobinostat Produces Objective Responses in Advanced Hodgkin's Lymphoma
 

Trial Sites

Name
Address
City
State
Zip
Country
Tokyo
Japan